The study aims to analyze and forecast the healthcare imaging market in China (2017–2021).
Research scope: Market trends, competitive structure, market metrics, market share, revenues, strategy, and government policies and initiatives.
Regional scope: China (excluding Hong Kong)
The study includes in-depth analysis of government-driven reforms, covering spending patterns, local manufacturers’ market situations, group purchasing practices, development of imaging centers, and public healthcare provision, from primary to tertiary care. Products covered include
X-ray, ultrasound, CT, MRI, and nuclear imaging (PET/SPECT) systems. CT and MRI are becoming ubiquitous hospital items, with high market penetration and adoption. PET/SPECT remains niche, with slower growth.
Various past practices have enabled favoritism across the country. The China government has taken this issue head-on in its development plan, changing regulations and purchasing channels, while also changing the landscape for both local and international brands, with each trying to establish and re-develop during the change.
The study also highlights 11 key market themes and offers a glimpse into the future direction of the imaging market in China. It tracks the movement and investment direction by both public and private initiatives in the different regions of China, with emphasis on manufacturers, distributors, and public and private hospitals, as well as the differences between the different hospitals tiers and cities. It explores the historical context for why China is implementing the reforms and assesses the impact towards the strategy for affordable equipment, high-end imaging systems, integrated systems, selection routes on the different types and categories of medical imaging manufacturers, positioning, regulatory directions, and China’s approach toward Big Data, highlighting the drivers and priorities in the development platform, procurement, and manufacturing of healthcare imaging systems. Th